FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:588-589 August 31, 1995 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

We now have another drug for the treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM). After more than a decade of clinical experience in Europe, Canada, and other countries,^1,2 the Food and Drug Administration (FDA) has approved metformin, marketed in the United States as Glucophage. Much of the FDA's caution can be attributed to the chemical similarity between metformin and phenformin, a drug that was used extensively in the 1960s but removed from the U.S. market in 1977 because of the excessive occurrence of lactic acidosis in patients treated with it.

This issue of the Journal contains two articles about . . . [Full Text of this Article]

References

References

This article has been cited by other articles:

• Spiller, H. A., Sawyer, T. S. (2006). Toxicology of oral antidiabetic medications. Am J Health Syst Pharm 63: 929-938 [Abstract] [Full Text]  
• Misbin, R. I. (2004). The Phantom of Lactic Acidosis due to Metformin in Patients With Diabetes. Diabetes Care 27: 1791-1793 [Full Text]  
• Spiller, H. A, Quadrani, D. A (2004). Toxic Effects from Metformin Exposure. The Annals of Pharmacotherapy 38: 776-780 [Abstract] [Full Text]